PSNL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	161 621
Average Volume	346 264
Market Cap	65.66M
EPS	$0 ( 2024-02-28 )
Next earnings date	( $-0.440 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.580
ATR14	$0.00500 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Hall Christopher M	Buy	400 000	Stock Option (right to buy)
2024-03-15	Chen Richard	Buy	175 000	Stock Option (right to buy)
2024-03-15	Tachibana Aaron	Buy	175 000	Stock Option (right to buy)
2024-03-15	Moore Stephen Michael	Buy	100 000	Stock Option (right to buy)
2024-03-01	Myers Woodrow A Jr	Buy	10 000	Common Stock

INSIDER POWER
-62.28
Last 98 transactions
Buy: 3 908 824 \| Sell: 9 802 248

Volume Correlation

Long: -0.04 (neutral)

Short: 0.00 (neutral)

Signal:(45.236) Neutral

Personalis Inc Correlation

10 Most Positive Correlations
SNGX	0.825
NAOV	0.813
VYNE	0.803

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Personalis Inc Correlation - Currency/Commodity

-0.13
( neutral )

0.56
( weak )

0.00
( neutral )

-0.48
( neutral )

0.64
( weak )

0.24
( neutral )

Personalis Inc Financials

Annual	2023
Revenue:	$73.48M
Gross Profit:	$18.21M (24.78 %)
EPS:	$-2.25

Q4	2023
Revenue:	$19.68M
Gross Profit:	$5.21M (26.45 %)
EPS:	$-0.540

Q3	2023
Revenue:	$18.25M
Gross Profit:	$3.48M (19.08 %)
EPS:	$-0.600

Q2	2023
Revenue:	$16.70M
Gross Profit:	$4.79M (28.70 %)
EPS:	$-0.500

Financial Reports:

No articles found.

Personalis Inc

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.